abrilumab   Click here for help

GtoPdb Ligand ID: 11531

Synonyms: AMG 181 | AMG-181 | MEDI-7183 | MEDI7183
Immunopharmacology Ligand
Compound class: Antibody
Comment: Abrilumab (AMG-181, MEDI-7183) is a fully human IgG2κ monoclonal antibody which selectively targets α4β7 integrin heterodimers [1] that was developed by MedImmune. It was designed for the treatment of inflammatory bowel diseases (ulcerative colitis [2], and Crohn's disease).
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
Bioactivity Comments
Abrilumab is selective for α4β7 heterodimers and does not bind to α4β1 or αEβ7 integrins [1]. It does not disrupt VCAM-1-mediated T cell adhesion in the vascular endothelium.
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
integrin, alpha 4 subunit (antigen CD49D, alpha 4 subunit of VLA-4 receptor) Hs Antibody Inhibition 11.1 pKd - 1
⤷ pKd 11.1 (Kd 9x10-12 M) [1]
Description: Binding affinity for α4β7 receptors expressed on the surface of HuT78 cells.